Since their discovery in 1988, endothelins have attracted scientific interest because of their extremely potent and long lasting vasoconstrictive effects. In the clinical part of the study plasma and cerebrospinal fluid (CSF) concentrations of big @entity2232 , @entity2232 and @entity6423 in @entity1 with @entity510 ( @entity510 ) were measured serially for 2 weeks after the onset of @entity510 . Big @entity2232 was the predominant peptide present in CSF. The CSF concentrations of big @entity6422 were significantly higher in older than in younger @entity1 . In @entity1 with @entity2553 postoperative concentrations of endothelins in the CSF remained at or were increased above levels measured before surgery. The volume of @entity1410 in the basal cisterns was predictive of the concentrations of endothelins in CSF. In the experimental study the efficacy of the orally active endothelin-receptor-antagonist @entity12584 for the prevention of @entity2553 after experimental @entity510 , using the @entity235 two- @entity548 model, was investigated. Twenty-eight @entity235 were used in this laboratory experiment. Fourteen animals each were assigned to the treatment and to the control group. In the treatment group each @entity235 received two single doses of 30 mg/kg @entity12584 orally per day. The diameter of the basilar artery decreased from 1.36 +/- 0.17 mm at day 1 to 1.19 +/- 0.23 mm at day 8 in the treatment group while in the control group the vessel diameter decreased from 1.48 +/- 0.19 mm at day 1 to 1.02 +/- 0.22 mm at day 8. These results corresponded to a decrease of vessel diameter of 13.1% +/- 11.2% in the treatment group and a decrease of vessel diameter of 30.7% +/- 12.4% in the control group (p < 0.001). Concentrations of @entity2232 in CSF significantly increased with time after @entity510 . These results underline the important role of endothelin in the development of @entity2553 , and gives for the first time evidence that prevention of @entity2553 can be achieved by the endothelin-receptor-antagonist @entity12584 .

Endothelin in XXXX . Clinical and experimental results.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6422 :: ('1906;1908', 'Gene') :: ['ET-1, ET-1 and ET-3'] @entity12584 :: ('MESH:C086232', 'Chemical') :: ['RO 47-0203'] @entity510 :: ('MESH:D013345', 'Disease') :: ['aneurysmal subarachnoid hemorrhage', 'SAH'] @entity2232 :: ('1906', 'Gene') :: ['endothelin-1'] @entity235 :: ('9615', 'Species') :: ['canine', 'beagle dogs', 'dog'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematoma'] @entity6423 :: ('1908', 'Gene') :: ['endothelin-3'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['cerebral vasospasm']
@entity2553 :: (MESH:D020301,Disease) :: ['cerebral vasospasm']
